T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced that John McDonough, CEO of T2 Bio, will present at Oppenheimer’s 24th Annual Healthcare Conference, December 11, 2013, at 10:40am ET. Mr. McDonough will discuss how T2MR® assists in the management of sepsis, including the Company’s flagship diagnostic test, T2Candida®, which is currently in a pivotal clinical trial with results expected in 2014.
Help employers find you! Check out all the jobs and post your resume.
